Promising drug duo aims to stall recurrent uterine cancer
NCT ID NCT06366347
First seen Feb 17, 2026 · Last updated May 16, 2026 · Updated 7 times
Summary
This study tests whether two drugs, abemaciclib and letrozole, can help keep advanced or recurrent endometrial cancer from progressing. The trial enrolls 32 people with a specific type of cancer (ER-positive, mismatch repair proficient, TP53 wildtype). Participants take the drugs as maintenance therapy after initial treatment, and researchers track how long the cancer stays controlled and what side effects occur.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ENDOMETRIAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beth Israel Deaconess Medical Center
RECRUITINGBoston, Massachusetts, 02215, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Brigham and Women's Hospital
RECRUITINGBoston, Massachusetts, 02215, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Dana-Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02215, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Dana-Farber Cancer Institute at Foxborough
WITHDRAWNFoxborough, Massachusetts, 02035, United States
-
Dana-Farber Cancer Institute at Milford
WITHDRAWNMilford, Massachusetts, 01757, United States
-
Dana-Farber Cancer Institute at South Shore Hospital
RECRUITINGWeymouth, Massachusetts, 02190, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.